Top

International Journal of Clinical Pharmacy

Published in:

Open Access 01-08-2019 | Care | Commentary

A regulatory perspective on the availability of medicines and medicine shortages in outpatient care: case Finland

Authors: Kati Sarnola, Johanna Linnolahti

Published in: International Journal of Clinical Pharmacy | Issue 4/2019

Abstract

The good availability of medicines and medicine shortages have become global issues during recent years. Medicine shortages are often affected by universal determinants, but the availability of medicines is also depending on national characteristics. This commentary aims to discuss the issue of the availability of medicines and medicine shortages in outpatient care in Finland, taking in consideration both national characteristics and global determinants that effect on the availability of medicines in other countries but Finland also. In this commentary, a regulatory approach is applied.

Besancon L, Chaar B. Report of the international summit on medicines shortage 2013. Final report. Toronto (CA): International Pharmaceutical Federation; 2013; 24p.

Heiskanen K, Ahonen R, Karttunen P, Kanerva R, Timonen J. Medicine shortages—a study of community pharmacies in Finland. Health Policy. 2015;119(2):232–8.CrossRefPubMed

European Federation of Pharmaceutical Industries and Associations. The Pharmaceutical industry figures - Key Data 2018. Final Report. Brussels (BE): European Federation of Pharmaceutical Industries and Associations 2018; 28p.

Heiskanen K, Ahonen R, Kanerva R, Karttunen P, Timonen J. The reasons behind medicine shortages from the perspective of pharmaceutical companies and pharmaceutical wholesalers in Finland. PLoS ONE. 2017;12(6):e0179479.CrossRefPubMedPubMedCentral

Canadian Pharmacists Association. Canadian drug shortages survey. Final Report; 2010.

Pelkonen E. Ajankohtaista Suomen lääkejakelusta. [Current topics in Finnish pharmaceutical distribution]. In: Hanhela. Lääkkeistä terveyttä? Helsinki: Lääketietokeskus; 2010. p. 28–30.

Oriola Corporation. Helsinki: Oriola Corporation; 2017. www.oriola.com/publications/stock-exchange-releases/2017/oriola-corporations-third-quarter-result-impacted-by-distribution-disruptions-in-finlan. Accessed 12 April 2019.

Pharma Industry Finland. Helsinki: Pharma Industry Finland; 2019. http://www.pif.fi/en/medicine/medicine-distribution. Accessed 12 April 2019.

The Association of Finnish Pharmacies. Helsinki: The Association of Finnish Pharmacies; 2018. www.apteekkariliitto.fi/media/3-apteekkariliitto.fi/englanti/annual-reviews/annual_report_2017.pdf. Accessed 28 March 2019.

10.

The Association of Finnish Pharmacies. Helsinki: The Association of Finnish Pharmacies; 2013. www.apteekkariliitto.fi/media/pdf/afp_annual_review_2012_web.pdf. Accessed 28 March 2019.

11.

Pharmaceuticals Pricing Board. Helsinki: Pharmaceuticals Pricing Board; 2015. www.hila.fi/en/operations-and-organisation/tasks. Accessed 28 March 2019.

12.

Hakkarainen KM, Kivioja A, Saastamoinen LK. Drug prices in Finland. In: Babar Z-U-D, editor. Pharmaceutical prices in the 21st century. Cham: Springer International Publishing; 2015. p. 93–112.

13.

Pharmaceuticals Pricing Board. Helsinki: Pharmaceuticals Pricing Board; 2015. www.hila.fi/en/reference-price-system. Accessed 28 March 2019.

14.

The Social Insurance Institution of Finland. Helsinki: The Social Insurance Institution of Finland; 2018. www.kela.fi/web/en/medicine-expenses-generic-substitution-and-the-reference-price-system?inheritRedirect=true. Accessed 28 March 2019.

15.

Morrison A. Drug supply disruptions [environmental scan issue 17]. Final Report. Canadian Agency for Drugs and Technologies in Health; 2011.

16.

Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E, et al. Pharmaceutical regulation in 15 European countries review. Health Syst Transit. 2016;18(5):1–122.PubMed

17.

Medicine Act 10.4.1987/395. Finlex Data Bak; 2019. www.finlex.fi/en/. Accessed 12 April 2019.

18.

Finnish Medicines Agency. Helsinki: Finnish Medicines Agency; 2019. www.fimea.fi/web/en/supervision/mandatory_reserve_supplies. Accessed 28 March 2019.

19.

National Emergency Supply Agency. Helsinki: National Emergency Supply Agency; 2019. www.nesa.fi/organisation/funding-and-legislation/funding-the-security-of-supply/. Accessed 17 April 2019.

20.

European Commission and European Medicines Agency. Questions and answers related to the United Kingdom’s withdrawal from the European Union with regard to the medicinal products for human and veterinary use within the framework of the Centralised Procedure. Rev 04, 1 February 2019.

21.

European Commission. European Union; 2019. https://ec.europa.eu/info/brexit/brexit-preparedness_en. Accessed 12 April 2019.

22.

Heads of Medicines Agencies and the European Medicines Agency. Heads of Medicines Agencies and the European Medicines Agency; 2019. www.hma.eu/fileadmin/dateien/HMA_joint/00-_About_HMA/03-Working_Groups/TF_Availability/2018_08_TF_AAM_Press_release_Towards_Availability.pdf. Accessed 12 April 2019.

23.

Gamble C, Dudley L, Allam A, Bell P, Goodrare H, Hanley B, et al. Patient and public involvement in the early stages of clinical trial development: a systematic cohort investigation. BMJ Open. 2014;4(7):e005234.CrossRefPubMedPubMedCentral

24.

Sharma AE, Willard-Grace R, Willis A, Zieve O, Dubé K, Parker C, et al. How can we talk about patient-centered care without patients at the table? Lessons learned from patient advisory councils. J Am Board Fam Med. 2016;29(6):775–84.CrossRefPubMed

25.

Sjöström B. Sweden: Swedish Medicines Agency’s Patient- and Consumer Advisory Board; 2018. https://lakemedelsverket.se/upload/ovrigt/MPA_Patient-and-Consumer-Advisoy-Board-B-Sjostrom-LV-2.pdf. Accessed 28 March 2019.

Title: A regulatory perspective on the availability of medicines and medicine shortages in outpatient care: case Finland
Authors: Kati Sarnola
Johanna Linnolahti
Publication date: 01-08-2019
Publisher: Springer International Publishing
Keyword: Care
Published in: International Journal of Clinical Pharmacy / Issue 4/2019
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-019-00850-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A regulatory perspective on the availability of medicines and medicine shortages in outpatient care: case Finland

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Use of non-formulary high-cost medicines in an Australian public hospital

Pharmacy-supported interventions at transitions of care: an umbrella review

Pharmacists’ perspectives on medication reviews for long-term care residents with advanced dementia: a qualitative study

Potentially inappropriate medications in older kidney transplant recipients: a Brazilian prevalence study

The appropriateness of psychotropic medicines: an interview study of service users attending a substance misuse service in England

Health-related quality of life of exposed versus non-exposed androgen deprivation therapy patients with prostate cancer: a cross-sectional study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page